Malignant Fibrous Histiocytoma (MFH)

Author:
Topic updated on 05/24/13 6:55am
Introduction
  • A rare malignant histiocytic lesion of the bone
    • 25% arise as secondary lesion from bone infarct, Paget disease, or prior radiation
    • similar to presentation to fibrosarcoma but histologically different
  • Epidemiology
    • incidence
      • most common soft-tissue sarcoma in adults 55 to 80 years of age
    • demographics
      • male > female (2:1)
      • more common in Caucasians than African Americans or Asians
    • location
      • often metaphyseal of long bones
        • primarily distal femur, proximal tibia, proximal humerus
  • Genetics
    • unknown
  • Prognosis
    • 50% - 60% survival at 5 years
Presentation
  • History
    • painless mass
  • Symptoms
    • swelling
    • limp
    • fever
    • can present with pathologic fracture
Imaging
  • Radiographs
    • recommended views
      • AP and lateral of affected area
    • findings
      • lytic and destructive lesion often in the metaphysis 
      • variable periosteal reaction
      • cortical destruction with soft tissue mass
      • radiographs often non-specific
  • MRI scan
    • indications
      • necessary to better characterize lesion
    • findings
      • deep seated heterogeneous mass
      • T1- low signal
      • T2- high signal
  • Bone scan
    • hot
Studies
  • Labs
    • elevated WBC
    • hypoglycemia
  • Histology 
    • pleomorphic spindle cells and histiocytic cells in storiform pattern 
    • malignant multinucleated giant cells with grooved or indented nuclei 
    • chronic inflammatory cells
Treatment
  • Operative (similar to osteosarcoma)
    • neadjuntive chemotherapy, wide resection, postoperative chemotherapy +/- radiation
      • indications
        • standard of care
      • chemotherapy
        • preoperative chemotherapy given for 8-12 weeks followed by maintenance chemotherapy for 6-12 months after surgical resection
      • surgical resection
        • trend towards limb salvage whenever possible
      • radiation
        • indications
          • lesion > 5 cm
        • comon dossage
          • 5000cGy preoperatively
          • 1,400 to 2,000 cGy postoperatively or brachytherapy if margins close or positive
            • higher doses (6,300 to 6,600 cGy) show equal local control rates and lower postoperative wound complications but have a higher fibrosis incidence 
Differentials & Groups
 
 
Malignant destructive lesion in older patient(1)
 
Sacral lesions in older patients
 
Treated with wide resection and chemotherapy(2)
MFH / fibrosarcoma
 
 
Chondrosarcoma
 
 
 
Dedifferentiated chondrosarcoma
 
 
Metastatic disease
 
 
 
Lymphoma
 
 
 
Myeloma
 
 
 
Secondary sarcoma
 
 •
 
Osteosarcoma
 
 
 
 
Chordoma
 
 
 
 
Ewings
 
 
 
 
Rhabdomyosarcoma (soft tissue)
 
 
 
 
ASSUMPTIONS: (1) Younger patient is < 40 yrs; (2) assuming no impending fracture




 
IBank
  Location
Xray
Xray
CT
B. Scan
MRI
MRI
Histo(1)
Case A humerus
Case A femur
Case A femur
(1) - histology does not always correspond to case


 

Please Rate Educational Value!
3.0
Average 3.0 of 2 Ratings

Qbank (1 Questions)





Evidence & References Show References




Topic Comments

Subscribe status:

Page:1